- Home
- Our company
- Social impact
- Global health equity
- Improving access to care and services
Improving access to care and services
We collaborate with public and private sector organizations to expand access to care and services to improve global health.
Featured stories
Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New EffortDonation Program to be Part of Broader Initiative to Raise Awareness and Action
Johnson & Johnson secures a top spot on the 2016 Access to Medicine Index
The index looks at companies that do the best job of providing access to medications in developing countries. Johnson & Johnson ranked #2—and here’s why.
More from Johnson & Johnson
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
What is inflammation?
Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.
What is IL-23?
This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.